布地奈德混悬液联合复方异丙托溴铵溶液雾化吸入对慢阻肺急性加重期患者肺功能及血液相关指标的影响

Effects of budesonide suspension combined with compound ipratropium bromide solution aerosol inhalation on pulmonary function and blood related indexes in patients with acute exacerbation of chronic obstructive pulmonary disease

目的探讨临床针对慢性阻塞性肺疾病(慢阻肺)急性加重期患者予以布地奈德混悬液、复方异丙托溴铵溶液联合雾化吸入治疗,对其各项肺功能及血液相关指标的影响。方法90例慢阻肺急性加重期患者作为研究对象,随机分为对照组与观察组,各45例。对照组予以复方异丙托溴铵溶液雾化吸入治疗,观察组在对照组的基础上联合布地奈德混悬液雾化吸入治疗。对比两组患者治疗前后各项肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、第1秒用力呼气容积占用力肺活量比值(FEV1/FVC)、最大呼气流量(PEF)]及血液相关指标[动脉血二氧化碳分压(PaCO2)、动脉血氧分压(PaO2)、动脉血氧饱和度(SaO2)]变化情况。结果治疗后,观察组FEV1(2.12±0.89)L、FVC(4.67±0.68)L、FEV1/FVC(69.24±7.87)%、PEF(4.92±0.69)L/s水平均优于对照组的(1.59±0.51)L、(2.61±0.52)L、(58.23±6.23)%、(2.92±0.61)L/s,差异均具有统计学意义(P<0.05)。治疗后,观察组PaO2(70.34±5.32)mm Hg(1 mm Hg=0.133 kPa)、PaCO2(46.23±5.31)mm Hg、SaO2(90.43±11.12)%均优于对照组的(63.34±5.03)mm Hg、(56.43±6.02)mm Hg、(82.23±9.76)%,差异均具有统计学意义(P<0.05)。结论临床针对慢阻肺急性加重期患者予以布地奈德混悬液、复方异丙托溴铵溶液联合雾化吸入治疗效果明显,经用药治疗后可有效改善患者肺部通气状况及动脉血气指标,进而缓解其临床症状,控制病情进展,促进病情尽早康复。

Objective To discuss the effects of budesonide suspension combined with compound ipratropium bromide solution aerosol inhalation on pulmonary function and blood related indexes in patients with acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 90 patients with acute exacerbation of chronic obstructive pulmonary disease were studied and randomly divided into control group and observation group,with 45 cases in each group.The control group was treated with compound ipratropium bromide solution aerosol inhalation,and the observation group was treated with budesonide suspension aerosol inhalation on the basis of the control group.Both groups were compared in terms of pulmonary function indexes[forced expiratory volume in the 1st second(FEV1),forced vital capacity(FVC),FEV1/force vital capacity(FEV1/FVC),peak expiratory flow(PEF)]and blood-related indexes[arterial partial pressure of carbon dioxide(PaCO2),arterial partial pressure of oxygen(PaO2),arterial oxygen saturation(SaO2)]before and after treatment.Results After treatment,FEV1(2.12±0.89)L,FVC(4.67±0.68)L,FEV1/FVC(69.24±7.87)%,and PEF(4.92±0.69)L/s in the observation group were better than(1.59±0.51)L,(2.61±0.52)L,(58.23±6.23)%and(2.92±0.61)L/s in the control group,and all the differences were statistically significant(P<0.05).After treatment,PaO2(70.34±5.32)mm Hg(1 mm Hg=0.133 kPa),PaCO2(46.23±5.31)mm Hg,and SaO2(90.43±11.12)%in the observation group were better than(63.34±5.03)mm Hg,(56.43±6.02)mm Hg and(82.23±9.76)%in the control group,and the differences were statistically significant(P<0.05).Conclusion Budesonide suspension and compound ipratropium bromide solution combined with aerosol inhalation are effective in the treatment of acute exacerbation of chronic obstructive pulmonary disease,which can effectively improve the pulmonary ventilation and arterial blood gas index of patients,relieve the clinical symptoms,control the progress of the disease,and promote the recovery of patients as soon as possible.